Key Points {#FPar1}
==========

Despite their well-known adverse effects, drugs with anticholinergic properties (DAPs), especially antidepressants and antipsychotics, remain widely used among older, frail people living in residential care.Long-term care residents with dementia are being prescribed less DAPs compared with those without cognitive decline.As a favorable trend, the use of some of the high-burden DAPs, such as hydroxyzine, has practically disappeared over the years.

Introduction {#Sec1}
============

According to recent literature, the use of drugs with anticholinergic properties (DAPs) among older people living in long-term care varies between 12 and 77%, depending on various populations and criteria for anticholinergic drugs \[[@CR1]--[@CR5]\]. The use of DAPs is common, despite adverse effects such as dryness of mouth and constipation \[[@CR6]\], confusion, and even cognitive decline \[[@CR7], [@CR8]\]. There is also evidence that using DAPs worsens psychological well-being \[[@CR5], [@CR9]\]. Furthermore, a greater anticholinergic load may lead to worse outcomes than a moderate load \[[@CR6], [@CR10], [@CR11]\]. Much effort has been directed at defining potentially inappropriate medications (PIMs) for older people, and various lists and criteria have been created, such as the Beers list \[[@CR12]\] or STOPP/START \[[@CR13]\]. One of the important properties of PIMs is the anticholinergic effect. There are also various lists defining DAPs \[[@CR6], [@CR14], [@CR15]\]; however, no consensus has been reached on which of the developed criteria would be most useful in research or in clinical settings.

Some studies have investigated time trends in the prescribing and use of PIMs in older people \[[@CR16]--[@CR21]\]. However, to our knowledge, there are only a few studies examining temporal trends in prescribing anticholinergic drugs, and their results are controversial. An American register-based study investigated DAP use among older NH residents with Alzheimer's disease-related dementia from 2007 to 2008 \[[@CR2]\]. The use of DAPs was common, although there was a small but significant decrease in DAP use, from 77.1% in 2007 to 76.6% in 2008. Another American study explored trends of prescribing high-risk anticholinergic medications between 2006 and 2015 to older adults during outpatient visits \[[@CR22]\]. Of medications, 35 were determined as high-risk anticholinergics based on the Beers criteria and the Anticholinergic Risk Scale (ARS) \[[@CR6]\]. The prevalence of high-risk anticholinergic prescriptions remained stable during the study period. A Scottish register-based study \[[@CR23]\] examined the trends of anticholinergic drug prescriptions to older people, from 1995 to 2010, according to the modified ARS. A significantly higher proportion of the study population received anticholinergic medication in 2010 (23.7%) than in 1995 (20.7%). Only one of the studies mentioned above focused on a long-term care population, and in that study the study period was only 2 years. Thus, to our knowledge, our study is the first to investigate temporal trends of DAP use in long-term care over a relatively long period and with several assessment points.

The main objective of our study was to investigate 14-year temporal trends in the use and burden of DAPs according to ARS in long-term care facilities in Helsinki. Another aim was to clarify temporal trends in various drug groups of DAPs. Furthermore, we explored how dementia was associated with DAP use.

Methods {#Sec2}
=======

Study Design and Population {#Sec3}
---------------------------

Participants of this study were all older people permanently living in nursing homes (NHs) in 2003 (*n *=1987), 2011 (*n *=1576), and 2017 (*n *=791), and in assisted living facilities (ALFs) in 2007 (*n *=1377), 2011 (*n *=1586), and 2017 (*n *=1673) in Helsinki. Written informed consent was obtained from every participant or their proxy in case of moderate--severe dementia \[Clinical Dementia Rating (CDR) scale 2\] \[[@CR24]\]. Residents with severe dementia (CDR 2) \[[@CR24]\] and not having a close proxy to give informed consent were excluded. The response rate in NHs was 94% in 2003, 81% in 2011, and 68% in 2017, while the response rate in ALFs was 66% in 2007, 64% in 2011, and 62% in 2017.

Residents \< 65 years of age, those without medication charts, and those not using any drugs were excluded. After refusals and exclusions, 4297 subjects remained in the NH cohorts (2003, 2011, and 2017) and 4565 in the ALF cohorts (2007, 2011, and 2017).

In Finland, there are two kinds of long-term care facilities---NHs and ALFs. ALFs provide care around the clock, but the environment is more home-like. ALFs also include group homes for dementia patients. Compared with ALFs, residents in NHs have more comorbidities and poorer cognition and functioning. However, differences between the general state of health of residents in the two different settings have recently diminished \[[@CR25]\]. The number of registered nurses is higher in NHs than in ALFs. The current trend in Finland favors living at home with home-care assistance. Simultaneously, the number of beds has shifted from NHs towards ALFs, and long-term care beds in total have decreased.

In every participating unit, the data were gathered by trained registered nurses, and each resident was assessed over 1 day using a standardized protocol. Demographic data, diagnoses, and medication lists were retrieved from medical charts. Possible comorbid conditions were assessed using the Charlson Comorbidity Index (CCI) \[[@CR26]\], and residents' nutritional status was assessed using the Mini Nutritional Assessment (MNA) \[[@CR27]\]. The severity of dementia was graded using the CDR scale \[[@CR24]\] and its memory item. The ability to move was assessed using the MNA item (0 = bed- or wheelchair-bound; 1 = able to get out of bed, but does not go outside; 2 = able to go outside). The anticholinergic potential of medications was determined using the ARS \[[@CR6]\], and the anticholinergic burden was determined using the ARS score. The ARS ranks medications according to their anticholinergic potential on a scale ranging from 0 (no or low risk) to 3 (high anticholinergic potential), and the ARS score is created by summing up the points of each individual medication. Only medications used regularly were taken into consideration in counting the ARS score. All DAP medications were coded according to the Anatomical Therapeutic Chemical (ATC) classification system \[[@CR28]\] as follows: antipsychotics (N05A), antidepressants (N06A), anti-Parkinson drugs (N04B), urinary antispasmodics (G04BD), muscle relaxants (M03BX), and antihistamines for systemic use (R06A). Hydroxyzine (N05BB01) was studied by itself, and medicines for the gastrointestinal tract (metoclopramide, A03FA01; loperamide, A07DA03; and ranitidine, A02BA02) were studied together as a group.

The study protocol was approved by the Ethics Committee of Helsinki University Hospital.

Statistical Analysis {#Sec4}
--------------------

The descriptive statistics are presented as means with standard deviation (SD) or counts with percentages. The unadjusted hypothesis of linearity was tested using the Cochran--Armitage test or analysis of variance with an appropriate contrast. Adjusted hypothesis of linearity (orthogonal polynomial) was evaluated using generalized linear models (e.g. analysis of covariance and logistic models) with appropriate distribution and link function. Models included age, sex, and CCI as covariates. The bootstrap method was used when the theoretical distribution of the test statistics was unknown or in the case of violation of the assumptions (e.g. non-normality). The normality of variables was evaluated using the Shapiro--Wilk W test. The Stata 15.1 statistical package (StataCorp LP, College Station, TX, USA) was used for the analysis.

Results {#Sec5}
=======

In both NHs (Table [1](#Tab1){ref-type="table"}) and ALFs (Table [2](#Tab2){ref-type="table"}), the proportion of female residents has decreased over the years. The mean age of residents was almost 85 years and remained stable over the study period in both settings. In recent cohorts, the diagnosis of dementia became more prevalent in both settings and the residents were more dependent on another person's assistance in mobility.Table 1Characteristics of residents in nursing homes in 2003, 2011, and 20172003 (*n *=1979)2011 (*n *=1568)2017 (*n *=750)*p* for trend*p* for trend\*Female1597 (80.7)1209 (77.1)580 (77.3)0.013Age, years \[mean (SD)\]84 (8)85 (8)84 (8)0.34Education \< 8 years1056 (53.4)634 (40.4)271 (36.1)\< 0.001Prior stroke539 (27.2)450 (28.7)215 (28.7)0.57Dementia1374 (69.4)1188 (76.6)581 (77.5)\< 0.001Cancer204 (10.3)127 (8.1)74 (9.9)0.048Bed- or wheelchair-bound598 (30.2)947 (60.4)427 (56.9)\< 0.001MNA \[[@CR27]\]0.37Malnourished, \< 17 points560 (28.3)494 (31.5)139 (18.5)At risk for malnutrition, 17--23 points1196 (60.4)969 (61.8)432 (57.6)Well-nourished, ≥ 23.5 points223 (11.3)103 (6.6)77 (10.3)CCI \[mean (SD)\] \[[@CR26]\]2.1 (1.2)2.4 (1.5)2.1 (1.3)0.39No. of medications used regularly \[mean (SD)\]7.9 (3.5)7.3 (3.3)8.3 (3.3)0.94Users of DAPs^a^1036 (52.3)720 (45.9)393 (52.4)0.190.29ARS score \[mean (SD)\] \[[@CR6]\]1.1 (1.5)0.8 (1.2)0.8 (1.1)\< 0.001\< 0.001Antipsychotics^a^633 (32.0)419 (26.7)245 (32.7)0.470.47Antidepressants^a^331 (16.7)309 (19.7)169 (22.5)\< 0.001\< 0.001Anti-Parkinson drugs^a^99 (5.0)57 (3.6)19 (2.5)0.0020.003Urinary antispasmodics^a^60 (3.0)2 (0.1)0 (0)\< 0.001\< 0.001Skeletal muscle relaxants^a^22 (1.1)43 (2.7)15 (2.0)0.0130.014Antihistamines for systemic use^a^7 (0.4)20 (1.3)2 (0.3)0.210.30Hydroxyzine142 (7.2)26 (1.7)4 (0.5)\< 0.001\< 0.001Gastrointestinal drugs^a,b^44 (2.2)13 (0.8)7 (0.9)\< 0.0010.003Data are expressed as *n* (%) unless otherwise specified*SD* standard deviation, *MNA* Mini Nutritional Assessment, *CCI* Charlson Comorbidity Index, *DAPS* drugs with anticholinergic properties, *ARS* Anticholinergic Risk Scale\**p* for trend; adjusted for age, sex, and CCI^a^Defined by the ARS \[[@CR6]\]^b^Including metoclopramide, loperamide, and ranitidineTable 2Characteristics of residents living in assisted living facilities in 2007, 2011, and 20172007 (*n *=1336)2011 (*n *=1556)2017 (*n *=1673)*p* for trend*p* for trend\*Female1041 (77.9)1217 (78.2)1210 (72.3)\< 0.001Age, years \[mean (SD)\]83 (7)84 (7)84 (8)0.006Education \< 8 years666 (49.9)744 (47.8)655 (39.2)\< 0.001Prior stroke343 (25.7)404 (26.0)362 (21.6)0.002Dementia798 (59.7)1090 (70.1)1302 (77.8)\< 0.001Cancer187 (14.0)140 (9.0)189 (11.3)0.19Bed- or wheelchair-bound195 (14.6)446 (28.7)508 (30.4)\< 0.001MNA \[[@CR27]\]0.63Malnourished, \< 17 points167 (12.5)311 (20.0)243 (14.5)At risk for malnutrition, 17--23 points880 (65.9)960 (61.7)979 (58.5)Well-nourished, ≥ 23.5 points289 (21.6)277 (17.8)318 (19.0)CCI \[mean (SD)\] \[[@CR26]\]2.1 (1.4)2.4 (1.5)2.0 (1.3)0.001No. of medications used regularly \[mean (SD)\]8.3 (3.5)8.8 (3.8)9.0 (3.7)\< 0.001Users of DAPs^a^551 (41.2)788 (50.6)899 (53.7)\< 0.001\< 0.001ARS score \[mean (SD)\]0.8 (1.2)0.8 (1.1)0.8 (1.0)0.230.081Antipsychotics^a^344 (25.7)489 (31.4)566 (33.8)\< 0.001\< 0.001Antidepressants^a^193 (14.4)350 (22.5)400 (23.9)\< 0.001\< 0.001Anti-Parkinson drugs^a^58 (4.3)51 (3.3)57 (3.4)0.300.20Urinary antispasmodics^a^31 (2.3)10 (0.6)0 (0)\< 0.001\< 0.001Skeletal muscle relaxants^a^17 (1.3)13 (0.8)25 (1.5)0.310.21Antihistamines for systemic use^a^1 (0.1)3 (0.2)6 (0.4)0.0910.10Hydroxyzine30 (2.2)26 (1.7)6 (0.4)\< 0.001\< 0.001Gastrointestinal drugs^a,b^11 (0.8)16 (1.0)12 (0.7)0.560.69Data are expressed as *n* (%) unless otherwise specified*SD* standard deviation, *MNA* Mini Nutritional Assessment, *CCI* Charlson Comorbidity Index, *DAPs* drugs with anticholinergic properties, *ARS* Anticholinergic Risk Scale\**p* for trend; adjusted for age, sex, and CCI^a^Defined by the ARS \[[@CR6]\]^b^Including metoclopramide, loperamide, and ranitidine

In NHs, no significant trend was observed in the mean number of all drugs used or in the proportion of DAP users over the years; however, there was a slightly decreasing trend in the ARS score (*p *\<0.001). In ALFs, the mean number of medications increased over time (*p *\<0.001). In addition, the proportion of residents using DAPs showed an increasing trend (*p *\<0.001). In contrast to NHs, the mean ARS score did not show a decreasing trend in ALFs (*p *=0.23). We further tested the temporal trends of the use of ARS-defined DAPs with high anticholinergic properties (drugs with an ARS score of 2 or 3). In NHs, a significant decreasing trend was observed from 2003 (mean score 0.59, SD 1.2) to 2011 (mean score 0.33, SD 0.9), and to 2017 (mean score 0.29, SD 0.8) \[*p* \< 0.001\]. In ALFs, no such trend was observed (data not shown).

The most widely used DAP drug groups defined by the ARS were antipsychotics and antidepressants. In NHs, an increasing trend in the proportion of residents using antidepressants was observed during 2003--2017. In antipsychotics users, no significant differences were seen between different years in NHs. In ALFs, an increasing trend was observed in the users of antipsychotics and antidepressants during a 10-year period. The increased use of antidepressants was mostly explained by the increased use of mirtazapine, which increased from 15.7 to 22.7% in NHs, and from 14.0 to 23.8% in ALFs. The use of tricyclic antidepressants practically disappeared, diminishing from 2.3 to 0.3% in NHs, and from 2.0 to 0.5% in ALFs.

The use of anti-Parkinson drugs and gastrointestinal drugs declined over the years in NHs, whereas use remained stable in ALFs. In both settings, there was a considerable decline in the number of users of urinary antispasmodics (oxybutynin and tolterodine) and hydroxyzine over the years studied. As a result, these medications were virtually phased out in 2017. Adjusting for age, sex, and CCI did not change the results.

To further investigate how dementia affects the use of DAPs, we stratified the DAP users according to diagnosis of dementia. In NHs, the ARS score decreased from 2003 to 2017 (*p* \< 0.001 for years). Residents with dementia had lower ARS scores than those without dementia (*p* \< 0.001 for dementia) and there was an interaction (*p *=0.003). Among residents in ALFs, the ARS score showed a slightly increasing trend during 2007--2017 for the whole cohort (*p* \< 0.001 for years). Similarly, as in NHs, residents in ALFs with dementia had lower ARS scores (*p* \< 0.001 for dementia) and there was an interaction (*p *=0.003), thus indicating that the direction of the trend differs significantly between those with and without dementia (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Mean ARS \[[@CR6]\] score in NH and ALF residents with and without dementia, from 2003 to 2017, adjusted for age and sex. *ARS* Anticholinergic Risk Scale, *NH* nursing home, *ALF* assisted living facilities

We then stratified users of antipsychotics according to diagnosis of dementia. In NHs, there was no difference between the years (*p *=0.43) or between those with or without dementia (*p *=0.42 for dementia); however, there was an interaction (*p *=0.002). In ALFs, by contrast, the proportion of users of antipsychotics increased over time (*p *\<0.001 for years), the use was more prevalent among those with dementia (*p *\<0.001 for dementia), and there was an interaction (*p *=0.003), suggesting that there was a faster increase of antipsychotic use among people without dementia than among those with dementia (Fig. [2](#Fig2){ref-type="fig"}). Similarly, users of antidepressants were stratified according to diagnosis of dementia. In NHs, among residents with dementia, an increasing trend in users of antidepressants was observed, whereas among those not having a dementia diagnosis, users of antidepressants first increased from 2003 to 2011 and then decreased towards 2017 (*p *=0.002 for years, *p *=0.012 for dementia, *p *=0.005 for interaction). In ALFs, users of antidepressants increased over the years (*p *\<0.001 for years), no significant difference was seen between those with and without dementia, and no interaction was present (*p *=0.55 for dementia, *p *=0.95 for interaction) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2Users (%) of the ARS \[[@CR6]\] defined antipsychotics in NH and ALF residents with and without dementia, from 2003 to 2017, adjusted for age and sex. *ARS* Anticholinergic Risk Scale, *NH* nursing home, *ALF* assisted living facilitiesFig. 3Users (%) of the ARS \[[@CR6]\] defined antidepressants in NH and ALF residents with and without dementia, from 2003 to 2017, adjusted for age and sex. *ARS* Anticholinergic Risk Scale, *NH* nursing home, *ALF* assisted living facilities

Discussion {#Sec6}
==========

Despite the well-known harms of DAPs, approximately half of the residents in both long-term care settings were regularly administered DAPs. In ALFs, there was even an increasing trend in DAP users. Although the ARS score did not increase in ALFs, and even decreased in NHs, there was a worrisome increasing trend in the users of ARS-defined antidepressants. This was explained by the increased use of mirtazapine, while the use of tricyclics nearly disappeared over the years. In both settings, residents with dementia tended to have a smaller anticholinergic load than those without a diagnosis of dementia, indicating that physicians are likely to avoid prescribing DAPs to residents with cognitive decline. Some other positive changes were also seen, as the use of ARS-defined urinary antispasmodics and hydroxyzine had virtually been phased out during the study period.

The main strength of this study is the large sample size of different cohorts within the time period examined. The study population is representative of the aged population with cognitive decline and deficits in functioning living in long-term care facilities. The data were collected from participants' medical charts by trained registered nurses using the same protocols, resulting in high internal validity. The ARS \[[@CR6]\] is an internationally widely used set of criteria for describing DAPs, and it also allows calculation of the total anticholinergic burden. To our knowledge, this is the first study to explore time trends in DAP use over such a long period in long-term care facilities.

One limitation of the study is that the participants were coded, thus it was not possible to follow particular persons and the real changes in their medications or health status. However, it is known that, on average, residents live less than 2 years in long-term care, and thus the follow-up of a particular person would not be possible in any case in such a study. The response rate decreased over the years and is markedly lower in ALFs than in NHs, possibly resulting in some bias. There was a marked increase in the proportion of patients with dementia in both settings, indicating problems in acquiring informed consent. In addition, organizing the study demanded extra work from the nursing staff, which is the most likely reason for the lower response rates in ALFs than in NHs.

There is a difference in the competence of nursing staff between NHs and ALFs. Whereas in NHs there was a significant decrease in the use of DAPs with high anticholinergic properties, no such trend was observed in ALFs. During the years 2003--2017, there has been a transition in institutionalized care in Helsinki as the amount of beds in NHs have decreased and increased in ALFs. Simultaneously, the aim has been to enable older people to live in their homes longer, and the criteria to enter long-term care facilities have somewhat tightened. As a result, residents entering ALFs currently have more often cognitive decline than in the earlier years. During this transition, the nursing staff in ALFs, already being relatively smaller per resident than in NHs, might not have received enough education regarding non-pharmaceutical approaches in the care of dementia patients. In NHs, the proportion of residents with dementia diagnosis has also increased, although not as sharply as in ALFs. In NHs, the nursing staff are likely to have experience and better know-how in taking care of residents with cognitive problems and associated psychological and behavior problems.

Our findings regarding a stable or increasing trend of users of DAPs is in line with previous studies \[[@CR22], [@CR23]\]. Contrary to the Scottish study \[[@CR23]\] exploring time trends in the use of DAPs, the ARS score did not increase in our settings, and even slightly decreased in NHs. In the Scottish study, the residents in care homes had a higher anticholinergic burden than home-dwelling older people \[[@CR23]\].

The most prevalent DAP groups in our study were antipsychotics and antidepressants, which is consistent with previous studies \[[@CR2], [@CR4], [@CR22]\]. Among ARS-defined antidepressants, mirtazapine was mostly responsible for the increase in antidepressant use. In addition to its antidepressant effect, mirtazapine has recently been used as a sedative agent for the treatment of insomnia, although strong evidence is lacking for such off-label use, especially among people with dementia \[[@CR29], [@CR30]\]. In fact, in 2017, 86.9% of our total mirtazapine users in NHs and ALFs received a dose of 15 mg or less. According to the ARS, mirtazapine is rated as having moderate anticholinergic potential. Therefore, as the ARS burden does not consider the dose \[[@CR6]\], the anticholinergic burden arising from mirtazapine use among our participants may be an overestimation of the true load. Nevertheless, physicians tend to consider mirtazapine a safer alternative to traditional hypnotics, and it has obviously replaced some of these traditional hypnotics. While mirtazapine use has increased, a decreasing trend in anxiolytics and hypnotics was observed in a Finnish study investigating the trends regarding the use of psychotropics \[[@CR31]\].

The use of ARS-defined antipsychotics remained high compared with previous studies \[[@CR4], [@CR18], [@CR32]--[@CR34]\]. However, some DAP scales do not consider, for example, antipsychotics, such as haloperidol, perphenazine, or risperidone, having anticholinergic properties \[[@CR14]\]. A positive point is that the traditional neuroleptics have been replaced totally by atypical antipsychotics, which have less anticholinergic properties and overall are considered to have less extrapyramidal adverse effects.

Some favorable trends in DAP use in our samples were observed. For example, the use of oxybutynin and tolterodine ceased during the study period. In an American study, the prevalence of urinary antispasmodics was 5.2--6% among the aged community-dwelling population with impaired cognition \[[@CR35]\], and, in a Norwegian NH population, antispasmodics were used by 2.4% of the study population \[[@CR18]\]. Similarly, the use of hydroxyzine has been discontinued. In addition, the use of gastrointestinal DAPs (metoclopramide, loperamide, and ranitidine) was lower than in earlier studies \[[@CR36], [@CR37]\]. However, our study did not include medications administered *pro re nata*, as did the Norwegian study in the case of metoclopramide \[[@CR36]\]. Furthermore, in recent years, the prescribing of histamine H2-receptor antagonists has been replaced mainly by proton pump inhibitors.

Over the study period, the total anticholinergic burden decreased in NHs, but increased slightly in ALFs. The total DAP burden was lower among residents with dementia than among those without dementia. This is in line with a Norwegian study in an NH population \[[@CR38]\]. However, there are also controversial results, depending on the study population and the DAP scale used \[[@CR39]\]. In an American study in NHs, dementia was negatively associated with low-level anticholinergic burden, but, instead, dementia increased the risk of high-level anticholinergic burden \[[@CR4]\].

Our hypothesis was that the use of DAPs would have decreased during the 14-year follow-up due to increased knowledge regarding the harms of these medications. In some drug classes, this was the case, perhaps because there are well-known alternatives with less anticholinergic properties, e.g. urinary antispasmodics such as mirabegron. In other classes, such as antidepressants and antipsychotics, there might be fewer alternative medications for older people.

Conclusions {#Sec7}
===========

Despite well-known harms of DAPs, approximately half of the residents in long-term care are administered these medications. A large proportion of old, high-burden DAPs have disappeared over the years, whereas mirtazapine has become increasingly prevalent in institutional settings. In NHs, the anticholinergic burden has decreased, but has remained stable in ALFs. A positive finding is that less DAPs were prescribed to residents with dementia than to those without dementia, suggesting that physicians are aware of the cognitive adverse effects of DAPs.
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